Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Bob Swift who wrote (2534)	4/25/1999 12:59:00 AM
From: Thomas M.	Read Replies (1) \| Respond to of 10280

Interesting tidbit from the article: Celexa supposedly has a better side effect profile than Prozac, et al. Tom

To: Bob Swift who wrote (2534)	4/25/1999 11:43:00 AM
From: Biomaven	Respond to of 10280

I actually own a little FRX, bought about a year ago at around 30. I bought based on Celexa, because in Europe it is actually the biggest selling anti-depressant. It does have a good side-effect profile, particularly for old people who take a lot of other drugs. It has around 7% of the market now, and I wouldn't be surprised to see it end up with 20%. If it does, FRX should do well. Interestingly, they also have a single enantiomer version in the works, (also developed by the drugs original developer). No details yet on its advantages, other than it will effectively extend the patent life. Peter

To: Bob Swift who wrote (2534)	4/25/1999 2:53:00 PM
From: rkrw	Read Replies (2) \| Respond to of 10280

I own shares in FRX. I believe they can earn $2 a share this fiscal year, so a PE of closer to 24, not over 100. Celexa has been doing great. Their single isomer version is in Phase III. I am unclear on what the arrangement with WLA will be for it. On a related note, it does show how an SSRI with a more modest side effect profile can break into the market. Hopefully the single isomer version of prozac will stack up well against celexa and racemic prozac. The Sepracor annual report arrived on Friday. In case anyone missed it, two new drugs listed, including Serevant, which is the world's leading drug (brand sales) for asthma with $700M in 1998 sales. Another potential coup and a logical licensing candidate for Glaxo.